Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents.
Evaluation of early bactericidal activity (EBA) by the determination of a fall in viable colony-forming units (CFU) of Mycobacterium tuberculosis in sputum is a first step in the clinical study of new antituberculosis agents. The time to detection (TTD) of growth in liquid media is more sensitive and could substitute for CFU counting on solid media. Overnight sputum samples collected during the evaluation of the novel agent TMC207 in comparison to isoniazid and rifampicin were studied. For the determination of CFU, we incubated 10-fold dilutions of homogenized sputum on selective 7H10 agar. The TTD was measured by incubating decontaminated sputum in the BACTEC MGIT 960 system. The fall in bacillary load over 7 days determined by CFU counting closely matched the prolongation of the TTD in the BACTEC MGIT 960 system. The CFU counts correlated significantly with the TTD. While the ranking of agents and different dosages of TMC207 was similar, the highest dose of TMC207 showed markedly better activity when measured by the TTD than CFU counting when compared to the activity of isoniazid. Automated TTD could augment, or, in future, replace, CFU counting to determine sputum bacillary load in EBA clinical trials pending a more formal evaluation of the correlation of the measurements.
Diacon
A H
AH
Department of Molecular Biology and Human Genetics, and MRC Centre for Molecular and Cellular Biology, DST/NRF Centre of Excellence for Biomedical TB Research, Faculty of Health Sciences, Stellenbosch University, Tygerberg, South Africa. ahd@sun.ac.za
Maritz
J S
JS
Venter
A
A
van Helden
P D
PD
Andries
K
K
McNeeley
D F
DF
Donald
P R
PR
D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015169:Colony Count, Microbial; D003470:Culture Media; D064687:Diarylquinolines; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000254:growth & development*; D011804:Quinolines / Q000008:administration & dosage / Q000494:pharmacology*; D012293:Rifampin / Q000008:administration & dosage / Q000494:pharmacology; D013183:Sputum / Q000382:microbiology; D013997:Time Factors; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology*; D055815:Young Adult
D000995:Antitubercular Agents; D003470:Culture Media; D064687:Diarylquinolines; D011804:Quinolines; C493870:bedaquiline; D007538:Isoniazid; D012293:Rifampin
J Clin Microbiol. 1999 Mar;37(3):748-52
9986844
Int J Tuberc Lung Dis. 2008 Jul;12(7):792-8
18544206
Chest. 1998 Feb;113(2):379-86
9498955
Science. 2005 Jan 14;307(5707):223-7
15591164
J Clin Microbiol. 1999 May;37(5):1366-9
10203488
Future Microbiol. 2010 Jun;5(6):849-58
20521931
Curr Pharm Des. 2004;10(26):3285-95
15544516
Tuberculosis (Edinb). 2008 Aug;88 Suppl 1:S75-83
18762155
Tuberculosis (Edinb). 2001;81 Suppl 1:1-52
11530398
BMC Infect Dis. 2004 Nov 17;4:51
15548322
Tuberculosis (Edinb). 2008 Nov;88(6):624-30
18456556
J Clin Microbiol. 2010 Jan;48(1):46-51
19923475
Int J Tuberc Lung Dis. 2009 Dec;13(12):1572-5
19919781
Lancet Infect Dis. 2009 Mar;9(3):162-72
19246020
Expert Rev Anti Infect Ther. 2003 Jun;1(1):141-55
15482107
J Clin Microbiol. 1997 Feb;35(2):364-8
9003597
N Engl J Med. 2009 Jun 4;360(23):2397-405
19494215
Antimicrob Agents Chemother. 2008 Aug;52(8):2831-5
18505852
Am Rev Respir Dis. 1980 Jun;121(6):939-49
6774638
J Clin Microbiol. 2008 Jul;46(7):2212-5
18480227